An AstraZeneca drug failed to prolong the lives of patients with the rare but lethal cancer mesothelioma in a clinical trial, the company said today. Tremelimumab did not extend the lives of severely-ill patients when given on its own but the company said it is hopeful the drug will have a role to play in combination treatments.
“We are disappointed that tremelimumab monotherapy did not demonstrate a survival benefit in this patient population with no approved medicines beyond first-line treatment. However, we remain confident in tremelimumab’s clinical activity in combination, as shown in our recently published Study 006 trial of tremelimumab and durvalumab in non-small cell lung cancer,” Robert Iannone, Senior Vice President, Head of Immuno-Oncology, Global Medicines Development at AstraZeneca, said.
Tremelimumab is also being tested in combination with another of AstraZeneca’s immune-boosting drugs, durvalumab, in multiple tumor cases, including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers.
Mesothelioma is a deadly form of cancer that affects the lining of the lungs or abdomen. It is most often seen in patients who have been exposed to asbestos.